Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Trial ID or NCT#
NCT02736578
Status
NOT RECRUITING
Purpose
This phase 1-2 trial studies the side effects and best dose of cetuximab-IRDye 800CW when used with intraoperative imaging, to determine the utility of cetuximab-IRDye 800CW to identify and assess pancreatic cancer in patients undergoing surgery to remove the tumor. Cetuximab-IRDye 800CW may help doctors better identify cancer in the operating room by making the cancer visible when viewed through a fluorescent imaging system.
Official Title
Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging
Eligibility Criteria
Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Investigator(s)
George A. Poultsides, MD, MS
Hepatobiliary surgeon,
Pancreatic surgeon,
Liver surgeon,
Sarcoma specialist,
Gastrointestinal specialist,
Minimally invasive surgeon
Professor of Surgery (General Surgery)
Contact us to find out if this trial is right for you.
Contact
CCTO
650-498-7061
View on ClinicalTrials.gov
